STOCK TITAN

NEXGEL Secures Supply Agreement with AbbVie

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
NEXGEL, Inc. has announced a supply agreement with AbbVie Inc. for the provision of gel pads to be used with AbbVie's Rapid Acoustic Pulse device. The gel pads, based on NEXGEL's hydrogel technology, will be a crucial component of the body contouring device.
Positive
  • None.
Negative
  • None.

LANGHORNE, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that its subsidiary, CG Converting and Packaging, has executed a supply agreement with AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company to be a supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.

Leveraging NEXGEL's proprietary hydrogel technology, its gel pads will be an important component of the body contouring device.

“We are honored and excited that a company of AbbVie’s stature and reputation has selected our gel pad for use with their product,” stated Adam Levy, CEO at NEXGEL.

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2022, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com


FAQ

What is the supply agreement announced by NEXGEL, Inc.?

NEXGEL, Inc. has executed a supply agreement with AbbVie Inc. to provide gel pads for use with AbbVie's Rapid Acoustic Pulse device.

What are the products offered by NEXGEL, Inc.?

NEXGEL, Inc. is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications.

Who is AbbVie Inc.?

AbbVie Inc. is a global biopharmaceutical company.

What is the purpose of AbbVie's Rapid Acoustic Pulse device?

AbbVie's Rapid Acoustic Pulse device is being investigated for improvement in the appearance of cellulite.

What role will NEXGEL's gel pads play in AbbVie's body contouring device?

NEXGEL's gel pads, leveraging its proprietary hydrogel technology, will be an important component of AbbVie's body contouring device.

Who is the CEO of NEXGEL, Inc.?

The CEO of NEXGEL, Inc. is Adam Levy.

NexGel, Inc

NASDAQ:NXGL

NXGL Rankings

NXGL Latest News

NXGL Stock Data

32.49M
5.28M
20.09%
2.95%
0.4%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
LANGHORNE